SUBSCRIBE to our newsletter
A New Epilepsy Drug is Now Approved: Oxtellar XR™ is the first and only FDA-approved once-daily oxcarbazepine product and will be available in the first quarter 2013.
To introduce physicians to Oxtellar XR™, our approved epilepsy product, Supernus Pharmaceuticals will host local educational dinner meetings conducted by recognized experts.
Physicians may visit SEEN™ (Supernus Epilepsy Education Network) to register for an invitation and to learn about the benefit Oxtellar XR™ may offer their patients. Programs begin in March 2013.
(Adderall XR and Carbatrol are registeredtrademarks of and are marketed by Shire LLC.
SEEN is a trademark of Supernus Pharmaceuticals, Inc.Oxtellar XR is a trademark of Supernus Pharmaceuticals, Inc.)